Bora Wins Presidential Innovation Award, Award Prize Donation to Benefit Those Impacted by Earthquake

Taipei, Taiwan, 10th April 2024 – The Office of the President Taiwan today announced the winners of the 6th “Presidential Innovation” Award, and Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472) has been awarded as the winner of the “President Innovation Award for Service Innovation.” Bora is awarded for its significant efforts in supporting pharmaceutical companies with its best-in-class services. Companies partnering with Bora are able to deliver more innovative drugs at the most efficient cost and ahead of competition, which ultimately benefit patients around the world. Bora is the first pharmaceutical company to win the Award.

The Presidential Innovation Award, held biennially by the Office of the President Taiwan, represents the greatest honor conferred by the Head of State to recognize and encourage innovation in all sectors. The award commends individuals and companies who have demonstrated excellence across diverse fields including product development, technology, management, service, and culture, and who have made significant contributions to the national economy by fostering industry transformation through innovative and entrepreneurial initiatives. These efforts serve as a catalyst for inspiring others to pursue innovative economic development in Taiwan. The ultimate objective is to establish a comprehensive national innovation system that fosters competitive advantages in economic growth.

Mr. Bobby Sheng, Chairman and CEO of Bora Group, said: “I’m extremely excited and honored to receive the recognition together with all the team members at Bora, who all continue to overcome challenges with an innovative mindset, strong commitment, and unwavering determination. We are proud to be leaders in the critical and fast-growing biotech and pharmaceutical industry in Taiwan.”

“In addition to providing innovative services to our clients,” Mr. Sheng continued, “our commitment to social responsibility is another critical driver of our culture. The Bora team has decided to donate the prize money from the award to Mennonite Christian Hospital in Hualien, Taiwan, to help people impacted by the recent earthquake receive necessary support and resume their normal lives as soon as possible.”

CDMO has become a driving force in delivering against the rapid growth in the global medical and pharmaceutical industries. Bora now is the largest pharmaceutical manufacturer and the only one capable of providing CDMO services for both small molecules and biologics in Taiwan with global reach. With the completion of its first US acquisition last week, Bora becomes one of the largest oral solid dosage manufacturers in the US, and continues to pursue opportunities for scale and scope and to lead the Taiwan pharmaceutical industry for global markets.


About Bora Pharmaceuticals:
Founded in 2007, Bora Pharmaceutical Co., Ltd. (“Bora” or “the Company”, 6472.TW) is the largest pharmaceutical manufacturer in Taiwan with well-connected global distribution to supply more than 100 countries around the world. Bora is dedicated to becoming a global leader in pharmaceutical manufacturing by offering its clients the best quality, efficiency, and reliability. Contact us for more information.


Press Release Contact:
Angela Luan, Investor Relations Director
Phone: +886-2-2657-3350 #113

Please share this content with others who may benefit from it.
You may also be interested in
Bora Pharmaceuticals to Acquire US Pharma Manufacturer Upsher-Smith  for $210 Million in Transaction to Fuel Global Expansion

Bora Pharmaceuticals to Acquire US Pharma Manufacturer Upsher-Smith for $210 Million in Transaction to Fuel Global Expansion

Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”, TWSE: 6472), today announced that its Board of Directors has approved the acquisition of Upsher-Smith Laboratories, Inc. (“Upsher-Smith”), a generics manufacturer based in Minnesota, US, from shareholders, Sawai Group Holdings Co., Ltd. (JP), and Sumitomo Corporation of Americas, for a total consideration of up to US$210 million.